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Subtrochanteric Femoral Insufficiency Fracture 
Following Bisphosphonate Therapy for Osseous 
Metastases
Lisabeth A. Bush, M.D., and Felix S. Chew, M.D. 
We present the case of an insufficiency fracture of the femoral shaft in a 61-year-old man who 
had received bisphosphonate therapy to reduce the fracture risk from lytic renal cell carcinoma 
metastases to the spine. Approximately 1.5 years after beginning monthly intravenous infusions 
of zoledronic acid (Zometa), the patient complained of persistent thigh pain. Radionuclide bone 
scan showed mildly increased activity in the lateral subtrochanteric cortex of the right femur, 
where there was focally increased T2 signal on MRI and a small, triangular ridge or cortical beak 
on radiographs. The lesion was initially thought to represent a metastasis, but after the patient 
returned with a transverse femoral shaft fracture through the ridge following minimal trauma, 
MRI and biopsy of the lesion failed to show any evidence of tumor. We suggest that this fracture 
is similar to the low-energy proximal femoral shaft fractures recently reported in postmenopausal 
women who have received oral bisphosphonates for osteoporosis. Suppression of bone turnover 
may play a role in the development of these fractures.
Insufficiency fractures are by definition caused by 
a low-energy event, usually normal physiologic mus-
cular activity which fractures bone that is abnormal in 
mineralization, elasticity, or ability to repair injury [1, 
2]. Insufficiency fractures are distinguished from stress 
fractures, in which abnormal repetitive stress with inad-
equate time for recovery and repair of microscopic dam-
age leads to fracture of otherwise normal bone. Tumor 
or infection may also abnormally weaken bone focally, 
leading to pathologic fracture from a minimal trauma 
or low-energy event. Insufficiency fractures are known 
to occur in conditions of abnormal bone mineraliza-
tion, metabolism, and remodeling, such as Paget disease, 
osteomalacia or rickets, osteopetrosis, osteoporosis, 
Introduction
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osteogenesis imperfect, rheumatoid arthritis, radiated 
bone, fluorosis, pyknodysostosis, fibrous dysplasia, 
hyperparathyroidism, metabolic bone disease, and renal 
osteodystrophy [1-6].
Due to the strength of the subtrochanteric region of 
the femur, between the lesser trochanter and the junc-
tion of the proximal and middle third of the femoral 
shaft, fractures in this region are usually related to high-
energy trauma [5, 6], but rare cases of stress fractures 
in runners and athletes [8,9] and insufficiency fractures 
due to Paget disease, osteomalacia, pyknodysostosis, 
and fluorosis have been reported [3,5]. Insufficiency 
fractures in the subtrochanteric and middle third of 
the femur have recently been recognized in postmeno-
pausal women receiving oral bisphosphonate therapy for 
osteoporosis [5, 6, 10-12]. Characteristic features have 
been described with these fractures and a mechanism 
proposed: inadequate osteoclast activity to allow normal 
remodeling and repair of normally occurring microscop-
ic damage [5, 6, 10-12].
We present the case of an insufficiency fracture of 
the proximal femoral shaft in a 61-year-old man who 
was receiving intravenous bisphosphonate therapy to 
reduce the fracture risk of lytic spinal metastases from 
renal cell carcinoma. We suggest that this fracture is sim-
Figure 1. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Tc99m-MDP anterior and posterior 
whole body bone scan demonstrates a subtle region of fo-
cal uptake at the lateral subtrochanteric aspect of the right 
femur (arrow). Additional findings include metastatic spine 
lesions and prior nephrectomy.
Figure 2. 62-year-old man on bisphosphonate therapy for 
osseous metastases. AP radiograph of the right femur with 
a 1 cm bony excrescence projecting from the lateral aspect 
of the femoral cortex in the subtrochanteric region (arrow), 
corresponding with the abnormality seen on radionuclide 
bone scan.
ilar to the insufficiency fractures of the proximal femoral 
shaft described with oral bisphosphonate therapy, and 
that abnormal bone remodeling underlies this and other 
conditions that lead to insufficiency fractures of the 
subtrochanteric femoral shaft. stones [6]. There is no 
left or right predominance [8]. The stones themselves 
are typically composed of calcium phosphate or calcium 
carbonate in association with other salts and organic 
material such as glycoproteins, desquamated cellular 
residue, and mucopolysaccharides. Bacterial elements 
have not been identified at the core of a sialolith [9]. 
Some factors inherent to the submandibular gland tend 
to favor stone formation there like longer and larger 
caliber duct, flow against gravity, slower flow rates and 
higher alkalinity along with higher mucin and calcium 
content of the saliva [10]. The submandibular gland 
hosts the largest stones with the largest reported one 
being 6cm in length [11]. Most submandibular stones 
are found in the salivary duct (75 to 85% of cases) [12]. 
Hilar stones tend to become very large before becom-
ing symptomatic. Ductal stones are elongated in shape 
whereas hilar stones tend to be oval [13].
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A 62-year-old man presented with right thigh 
pain. Past medical history was significant for renal 
cell carcinoma. Because of metastases to the spine, the 
patient had been receiving intravenously administered 
zoledronic acid (Zometa), a bisphosphonate medication 
for approximately 1.5 years. Because of concern for pos-
sible metastatic disease in the femur, diagnostic imaging 
was obtained. A Tc99m-MDP bone scan demonstrated 
mildly increased focal uptake in the lateral cortex of 
the subtrochanteric femoral shaft (Fig. 1). Subsequent 
radiographs of the right femur demonstrated mild, dif-
fuse cortical thickening and a triangularly shaped focal 
ridge or beak projecting from the lateral cortex (Fig. 2). 
Due to the patient’s underlying malignancy, concern was 
raised for a potential impending pathologic fracture. An 
MRI performed at this point for re-staging for disease 
in the abdomen and pelvis coincidentally included a 
glimpse of this portion of the femur on a single ultrafast 
gradient sequence after the administration of gado-
linium contrast. The lateral cortex was slightly thickened 
and had a focus of abnormal high signal (Fig. 3), which 
was thought to be consistent with a metastatic deposit. 
The contralateral femur was normal in signal, however 
its diaphyseal cortex also appeared slightly thickened.
Case Report
Figure 3. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Pre-fracture MRI. Ultrafast gradient 
sequence following administration of gadolinium, performed 
to re-stage abdominal disease, yields a fortuitous glimpse 
of abnormally increased marrow signal at the level of the 
cortical ridge (arrow). 
Figure 4. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Subtrochanteric femur fracture which 
extends through the center of the cortical ridge seen on the 
prior radiographs. The distal component is posteromedially 
displaced and medially angulated. 
One month later, the patient slipped and twisted his 
leg in an awkward way while trying to catch his balance. 
While twisting, he felt his leg break, and then unable 
to bear weight, he fell to the floor. Radiographs of the 
fracture site showed a simple, transverse, subtrochanteric 
femoral shaft fracture that extended through the middle 
of the triangular cortical ridge seen on the earlier radio-
graph (Fig. 4). Due to persistent concern for metastasis, 
an MRI was obtained prior to operative fixation of the 
fracture. The MRI demonstrated marrow edema related 
to the fracture and hemorrhage in the surrounding soft 
tissues as would be expected following an acute fracture 
(Fig. 5), but no evidence of an enhancing mass lesion or 
tumor at the fracture site. The patient underwent surgi-
cal reduction and internal fixation with a Stryker gamma 
nail (Fig. 6). At the time of surgery, a curetted specimen 
of the bone was obtained. Histologic examination of this 
specimen confirmed the absence of metastatic disease. 
No osteoclasts were evident in any high power field (Fig. 
8); a finding thought to be consistent with bisphospho-
nate therapy. Follow up radiographs of the fracture site 
showed exuberant fracture callus (Fig. 7). 
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Because of its great strength in the healthy body, the 
subtrochanteric portion of the femoral shaft typically 
requires the application of considerable force to fracture. 
Its remodeling is stimulated as a center of maximal 
bending movement [6, 7]. If this remodeling is dysfunc-
tional or inadequate to repair accumulating microscopic 
damage, this maximal center of bending force becomes 
a critical site for fracture and potentially life threatening 
fractures can be caused by low-energy mechanisms [6, 
15].
Our patient experienced prodromal pain and had 
imaging studies with characteristic uptake on bone scan, 
abnormal signal on MRI, and formation of a ridge or 
beak at the site of impending fracture on a background 
of diffuse bilateral cortical thickening of the femoral 
diaphyses. He then incurred a subtrochanteric femoral 
fracture with a simple twisting motion of his femur. This 
low-energy mechanism of trauma is consistent with an 
insufficiency fracture and is likely related to inadequate 
remodeling response to accumulating damage as has 
been postulated by other authors [5, 6, 10-13]. The 
patients in other series were women taking oral forms 
of bisphosphonate medication, specifically alendronate 
and risedronate, for osteoporosis. However, it seems 
Discussion
Figure 5. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Subtrochanteric femur fracture MR 
images A-B. Increased T2 signal consistent with edema at 
the fracture site and slight cortical thickening at the lateral 
aspect of the fracture (arrow). No focal lesion or enhance-
ment to suggest neoplasm. 
Figure 6. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Postoperative radiograph. Reduced 
subtrochanteric femur fracture, bridged by a Stryker 
Gamma 11 x 40 nail that has been locked with a hip screw. 
Cortical thickening and characteristic ridge at the lateral 
aspect of the simple, transverse fracture are demonstrated 
(arrow). 
reasonable that this type of insufficiency fracture could 
be seen in men taking bisphosphonates for other clinical 
indications such as for decreasing the complications of 
lytic metastases. If these fractures are the result of a class 
effect of the bisphosphonate medications, this pattern 
would be seen with intravenous forms as well, such as 
in our patient who was receiving intravenous Zometa, a 
third generation bisphosphonate. Other rare but serious 
risks including osteonecrosis of the jaw, usually preceded 
by trauma, infection, or surgery and musculoskeletal 
pain have been linked to both oral and intravenous 
forms of bisphosphonate medications [13]. As in a 
significant percentage of the patients in the reports of 
oral bisphosphonate-related fractures, our patient expe-
rienced pre-fracture prodromal pain, had diffuse cortical 
thickening of the femoral diaphyses, a focal cortical 
beak at the site of subsequent fracture, and a low energy 
mechanism of fracture [6].
We believe it is important to raise awareness of the 
potential for insufficiency fractures in patients on long 
term, high dose, or IV bisphosphonates. There is clearly 
a need to find a balance between the important benefit 
of these medications in patients with osteoporosis, lytic 
metastases, and other conditions with increased fracture 
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Figure 8. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Curettage specimens from fracture site 
at (A) 20x, and (B) 40x demonstrate fragments of cortex. 
No osteoclasts are seen in any of the high powered fields 
reviewed for this patient. No evidence of abnormal bone 
remodeling or tumor was seen. 
Figure 7. 62-year-old man on bisphosphonate therapy for 
osseous metastases. Subtrochanteric femur fracture 6 
weeks after fixation. Calcified callus is present at the frac-
ture site (arrow).
risk with the possibility of osteoclast over-suppression 
incapacitating the normal remodeling response to 
microscopic damage and resulting in insufficiency 
fracture. Further research is needed to establish causality 
and determine the exact mechanism which causes this 
relationship whether it is indeed the accumulation of 
microdamage due to inadequate remodeling, a change in 
the elasticity/induced brittleness of the underlying bony 
trabeculae, or some other mechanism [14, 15]. Optimal 
protocols for the dosage and duration of bisphosphonate 
therapy and actions to take if a patient has an impend-
ing or completed insufficiency fracture while on these 
medications deserve additional consideration as bispho-
sphonates can also adversely affect fracture healing [10, 
14]. Their long dwell time and prolonged suppression of 
osteoclast activity in the bone can effect fracture healing 
in some patients months or perhaps even years after 
discontinuation so that additional steps may be needed 
to promote fracture healing [10, 14, 16, 17].
Familiarity with this pattern of clinical history and 
imaging findings allows the opportunity to recognize 
the impending fracture risk in patients with insuf-
ficiency fractures related to bisphosphonate induced 
over-suppression of osteoclast-dependant bone remodel-
ing. Knowledge of the potential for low-energy fractures 
and poor fracture healing in this patient population will 
facilitate better management to prevent fracture comple-
tion and promote healing. 
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